Tinengotinib has a unique binding mechanism away from the ATP binding pocket that enables it to target even newly resistant cancer cells. It overcomes acquired resistance by targeting FGFR2 kinase domain mutations. Essentially, by inhibiting a number of different kinases (a particular type of enzyme important for cell growth), the drug targets the spread of the cancer cells with their acquired resistant mutations.